Indoco Remedies has approved a strategic divestment of its ophthalmic business in India and select African markets, transferring the division to Sunways (India) Private Limited. 

 

The transaction, executed under an Agreement to Transfer Business (ATB), marks a clear portfolio reshuffle for Indoco as it sharpens its focus on core therapeutic areas while exiting a niche vertical with established operations.

 

For Sunways (India) Private Limited, the deal significantly strengthens its ophthalmology platform by integrating an existing operating business into its portfolio. The company—flagship of the Sunways group—already manufactures and markets a range of ophthalmology and ENT formulations, including sterile ophthalmic products.

 

“This divestment is an important step in sharpening our focus on core therapeutic areas with stronger potential. We are confident that Sunways will further build on the strengths of the ophthalmic division, leveraging its core competencies across markets. 

 

"At Indoco, we will continue to invest in innovation, quality and operational excellence, creating long-term value for our stakeholders and the communities we serve," said Aditi Panandikar, Managing Director.

 

From Sunways’ perspective, the acquisition is a deliberate expansion move aimed at deepening its presence in ophthalmology through an established product base.

 

“This transaction is aligned with our strategy of strengthening our ophthalmology business through the acquisition of an established operating portfolio. We believe the transferred business offers a strong strategic fit with our existing platform and capabilities, and we look forward to ensuring a smooth transition and continuity for customers, products and other stakeholders," said Bhadresh Shroff, Director - Sunways (India).

 

The deal underscores a broader trend in the pharmaceutical sector, where companies are increasingly streamlining portfolios while specialist players consolidate capabilities in focused therapeutic segments.